HeritageTwo Centuries of Medical Publishing: The Lancet Story

The Lancet was founded in 1823 by Thomas Wakley, a young English surgeon who had just won a libel suit against the corrupt appointment system at the Royal College of Surgeons. Wakley named his publication after the surgical instrument—the lancet scalpel—symbolizing his intent to cut through the entrenched privilege and secrecy that plagued early 19th-century British medicine.

The first issue appeared on October 5, 1823, priced at sixpence. From its inception, The Lancet distinguished itself by publishing verbatim transcripts of surgical lectures—an act of radical transparency that made medical education accessible beyond the elite who could afford private tuition. Within a year, the journal’s circulation had reached several thousand, and it had become both influential and controversial.

Throughout its 200-year history, The Lancet has been at the center of pivotal medical moments. It published Florence Nightingale’s pioneering statistical work on sanitation during the Crimean War, reports on the first antiseptic surgical techniques by Joseph Lister, and some of the earliest randomized controlled trials in the mid-20th century. This tradition of publishing landmark studies continues to define the journal’s reputation today.

Ownership transferred to Elsevier in 1991, which has since managed publication while the editorial operations have remained independent. The current editor-in-chief is Dr. Richard Horton, who has held the position since 1995—making him one of the longest-serving editors of any major medical journal.

2025 MetricsImpact Factor 109.0 — Among the Highest in All of Medicine

The Lancet’s Impact Factor of 109.0 for 2025 represents a remarkable achievement in scholarly publishing. To put this figure in perspective: an Impact Factor above 100 means that, on average, each article published in The Lancet in 2023 and 2024 received 109 citations in 2025 alone. Very few journals in any discipline achieve this threshold.

This rating places The Lancet at the very pinnacle of the Medicine, General & Internal category, where it consistently competes with the New England Journal of Medicine for the top position. The 2025 figure reflects the journal’s extraordinary ability to publish research that shapes clinical practice, health policy, and global health agendas worldwide.

PortfolioThe Lancet Family — A Specialty Journal for Every Field

One of The Lancet’s distinctive strengths is its family of specialty journals, each carrying the Lancet brand and editorial standards into specific medical disciplines. This portfolio strategy has allowed the Lancet name to maintain extraordinary visibility across virtually every area of clinical medicine.

Each specialty journal operates with its own editorial board and peer-review system while adhering to the core Lancet editorial philosophy: publishing research that will change clinical practice or health policy. The combined Impact Factor footprint of the Lancet family exceeds 500, making it arguably the most influential portfolio in medical publishing.

TrendHistorical Impact Factor Trajectory (2017–2025)

The Lancet’s Impact Factor has followed a dramatic upward trajectory over the past nine years, with particularly explosive growth during and after the COVID-19 pandemic. Understanding this trend is essential for researchers evaluating the journal’s evolving citation performance.

The 2021 peak of 168.9 represents one of the highest Impact Factors ever recorded for a general medical journal. This extraordinary figure was driven almost entirely by the journal’s central role in publishing early COVID-19 research—including the first major clinical descriptions of the disease, the first large treatment trials (RECOVERY, SOLIDARITY), and landmark vaccine efficacy studies. The subsequent decline in 2022 and 2023 reflects the normalization of citation patterns as the pandemic transitioned to an endemic phase.

The recovery to 109.0 in 2025 demonstrates that The Lancet has successfully maintained elevated citation performance beyond the pandemic bubble, driven by continued publication of high-impact clinical trials, global health studies, and major review articles.

ScopeWhat The Lancet Publishes — Global Health to Bedside Medicine

The Lancet publishes original research, reviews, commentary, and analysis across the full spectrum of human health. Unlike many specialty journals, it actively seeks papers with broad clinical or public health relevance. The editorial team prioritizes research that has the potential to change medical practice, inform health policy, or advance scientific understanding across disciplines.

The journal’s scope encompasses:

• Clinical trials — Large-scale randomized controlled trials, particularly those with international or multi-site designs
• Epidemiological studies — Population-level research on disease burden, risk factors, and health trends
• Global health — Research on health disparities, health systems, and disease control in low- and middle-income countries
• Public health — Policy-relevant studies on health promotion, disease prevention, and health system strengthening
• Health systems research — Studies on healthcare delivery, financing, and quality improvement
• Translational medicine — Research bridging basic science discoveries and clinical applications

A distinctive feature of The Lancet is its strong commitment to global health equity. The journal actively solicits and publishes research from low- and middle-income countries, and its editorial policies explicitly discourage the geographic bias that favors research from high-income nations. The Lancet also publishes regular Commission reports that synthesize evidence on major health challenges and provide policy recommendations—often cited thousands of times.

PandemicThe Lancet and COVID-19 — Defining the Scientific Response

No journal played a more visible role in the COVID-19 pandemic than The Lancet. From the first reports of an unexplained pneumonia cluster in Wuhan, China, The Lancet was at the forefront of disseminating critical scientific information to clinicians, policymakers, and the public worldwide.

In January 2020, The Lancet published the first major clinical description of COVID-19 patients, providing the global medical community with essential information about disease presentation, severity, and outcomes. Throughout 2020 and 2021, the journal published a remarkable volume of pandemic-related research, including:

• The RECOVERY trial results, which established dexamethasone as the first effective treatment for severe COVID-19—a finding estimated to have saved over one million lives globally
• The WHO SOLIDARITY trial, a massive international platform trial testing multiple repurposed treatments simultaneously
• Pivotal vaccine efficacy studies, including early results for the Oxford-AstraZeneca and Pfizer-BioNTech vaccines
• Landmark epidemiological studies tracking transmission dynamics, variant emergence, and pandemic trajectories across multiple countries
• Major Commission reports on the multisectoral response to COVID-19 and its long-term consequences

The journal’s COVID-19 coverage was not without controversy. In May 2020, The Lancet was forced to retract a high-profile study on hydroxychloroquine after serious questions were raised about the data source. The retraction—one of the most visible in recent publishing history—sparked extensive debate about peer review, data integrity, and the pressures of pandemic publishing. Editor Richard Horton acknowledged the episode as a “wake-up call” for the publishing industry.

Despite this setback, The Lancet’s overall contribution to pandemic science was extraordinary. The journal’s rapid review process—compressing months of evaluation into days—became a model for crisis publishing. Its open-access policy for COVID-19 articles ensured that critical findings reached the widest possible audience, including clinicians in resource-limited settings who could not afford subscription fees.

ComparisonThe “Big Four” Medical Journals — Lancet vs. NEJM, JAMA, BMJ

The Lancet is universally recognized as one of the “Big Four” general medical journals, alongside the New England Journal of Medicine (NEJM), JAMA (Journal of the American Medical Association), and the BMJ (British Medical Journal). Each occupies a distinct position in the medical publishing ecosystem, and researchers often face the decision of which of these prestigious outlets to target.

vs. NEJM: The NEJM is arguably The Lancet’s closest competitor and is often perceived as slightly more focused on US-based clinical trials and biomedical science. The Lancet, by contrast, has cultivated a more explicitly global orientation, with a stronger emphasis on health policy, social determinants of health, and research from low- and middle-income countries. The two journals frequently vie for the highest Impact Factor in medicine.

vs. JAMA: JAMA offers broader scope than the name suggests, publishing across all medical specialties. However, JAMA’s readership is predominantly North American, and its editorial priorities reflect US healthcare concerns. The Lancet’s international editorial board and explicit commitment to global health equity give it a different geographic reach and ideological positioning.

vs. BMJ: The BMJ and The Lancet share a British heritage but have evolved in markedly different directions. The BMJ has positioned itself as the journal of evidence-based medicine, with a strong emphasis on critical appraisal, medical ethics, and the human side of healthcare. The Lancet maintains a more traditional focus on publishing large-scale original research and review articles, with a more formal academic tone.

For authors, the choice among these four journals often depends on the geographic and disciplinary orientation of the research, the desired readership, and the specific editorial priorities of each journal at a given time. All four maintain exceptionally high rejection rates—typically above 90%—making acceptance at any of them a significant academic achievement.

SubmissionHow to Publish in The Lancet — Review Process & Author Guidelines

Publishing in The Lancet is among the most competitive endeavors in academic medicine. The journal receives thousands of submissions annually and accepts fewer than 10% of original research articles. Understanding the submission process and editorial expectations can significantly improve an author’s chances.

Pre-Submission Inquiry

The Lancet strongly encourages authors to submit a pre-submission inquiry before sending a full manuscript. This brief summary (typically 100-200 words) allows editors to assess whether the work falls within the journal’s scope and meets its threshold for novelty and impact. A positive pre-submission inquiry does not guarantee acceptance but does indicate that the editors are interested in considering the full manuscript.

Initial Editorial Assessment

All submitted manuscripts undergo a rapid initial assessment by the editorial team. At this stage, approximately 70-80% of submissions are rejected without external peer review. Manuscripts that pass this triage proceed to full peer review, typically involving at least two independent expert reviewers.

Peer Review Process

The Lancet employs a single-blinded peer review process: reviewers know the identity of authors, but authors do not know the identity of reviewers. Reviewers are asked to evaluate manuscripts on:

• Novelty and originality — Does the work represent a significant advance?
• Methodological rigor — Are the study design, analysis, and interpretation sound?
• Clinical or policy relevance — Will this research change practice?
• General interest — Is the topic of broad interest to The Lancet’s global readership?

Revision and Decision

Manuscripts that receive favorable reviews may be invited for revision. The Lancet distinguishes between minor revisions (typically requiring 1-2 weeks) and major revisions (requiring substantial additional work). Major revision requests should be viewed positively—they indicate editorial interest in the work. Final decisions are made by the editor-in-chief or a senior editor.

Formatting and Word Limits

Original research articles are limited to 3,000-4,000 words with a maximum of 30 references, though exceptions are made for large-scale studies. The journal uses a structured abstract format (Background, Methods, Findings, Interpretation, Funding) and requires registration of all clinical trials. Detailed guidelines are available on the journal’s website.

Article Processing Charges

The Lancet operates a hybrid open-access model. Authors of accepted articles can choose to make their work immediately open access by paying an Article Processing Charge (APC) of approximately $6,300 USD (2025 rate). Authors without funding for APCs may request a waiver. Subscription articles become freely available 12 months after publication.

FAQFrequently Asked Questions About The Lancet